Alnylam Pharmaceuticals Funding: $135M Raised, Series A
Alnylam Pharmaceuticals has raised $135M in total funding. Latest round: Series A. Backed by Arch.
Alnylam Pharmaceuticals funding overview
Alnylam Pharmaceuticals has raised $135M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in October 2024. The round record for Alnylam Pharmaceuticals runs through 2024; nothing later has been disclosed. Investors on record include Arch.
Alnylam Pharmaceuticals at a glance
Total raised
$135M
Latest round
Series A
Latest round date
October 2024
Notable investors
Arch
Frequently asked about Alnylam Pharmaceuticals funding
How much has Alnylam Pharmaceuticals raised?
Alnylam Pharmaceuticals has raised $135M in total disclosed funding across the rounds on record.
Who has invested in Alnylam Pharmaceuticals?
Arch are named among the investors backing Alnylam Pharmaceuticals.
What was the latest Alnylam Pharmaceuticals funding round?
The most recent disclosed round is a Series A, announced in October 2024.
Where is Alnylam Pharmaceuticals based?
No headquarters location is disclosed for Alnylam Pharmaceuticals.
When did Alnylam Pharmaceuticals last raise?
The last disclosed Alnylam Pharmaceuticals round closed in October 2024 at Series A.
We update the Alnylam Pharmaceuticals record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies and their backers are listed below.
